Stock Research: Eli Lilly

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Eli Lilly

NYSE:LLY US5324571083
30
  • Value
    33
  • Growth
    79
  • Safety
    Safety
    12
  • Combined
    22
  • Sentiment
    61
  • 360° View
    360° View
    30
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Eli Lilly and Company is a medicine company that discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. It operates in the pharmaceutical industry, with products including Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity, and Zepbound, among others. The company operates globally. In the last fiscal year, the company had a market cap of $731,415 million, profits of $36,624 million, and revenue of $45,043 million with 47,000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 30 (better than 30% compared with alternatives), overall professional sentiment and financial characteristics for the stock Eli Lilly are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Eli Lilly. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 79% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 12, which means that the share price of Eli Lilly is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 88% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 33, which means that the company has a financing structure that is riskier than those of 67% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Dividends USA
Employee Focus US
Diversity USA
Moonshot Tech
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 20 12 27
Growth
79 89 77 19
Safety
Safety
33 39 28 20
Sentiment
61 76 81 34
360° View
360° View
30 55 40 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
38 79 52 31
Opinions Change
90 62 52 48
Pro Holdings
n/a 48 91 45
Market Pulse
48 67 67 62
Sentiment
61 76 81 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 20 12 27
Growth
79 89 77 19
Safety Safety
33 39 28 20
Combined
22 43 22 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
29 24 9 24
Price vs. Earnings (P/E)
7 5 3 16
Price vs. Book (P/B)
1 1 1 4
Dividend Yield
79 84 85 86
Value
12 20 12 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
77 67 82 11
Profit Growth
78 90 29 36
Capital Growth
65 54 55 34
Stock Returns
23 69 87 87
Growth
79 89 77 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
15 18 19 13
Refinancing
15 14 17 7
Liquidity
91 61 89 93
Safety Safety
33 39 28 20

Similar Stocks

Discover high‑ranked alternatives to Eli Lilly and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.